CTLT - Sarepta in selloff after late-stage setback for Duchenne candidate
2023-10-31 09:14:03 ET
More on Sarepta
- Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
- Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst
- Sarepta Eyes Broadened Label For ELEVIDYS Amid Progress (Rating Upgrade)
- 5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more
- Sarepta Phase 3 study for DMD drug fails to meet primary endpoint
For further details see:
Sarepta in selloff after late-stage setback for Duchenne candidate